OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

Published:2018-04-24 Issue: Volume: Page:e1465164
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Nanni Patrizia¹^ORCID,De Giovanni Carla¹,Burocchi Alessia²,Nicoletti Giordano³^ORCID,Landuzzi Lorena³,Palladini Arianna¹^ORCID,Ianzano Marianna Lucia¹,Arioli Ivano²,Colombo Mario P.²^ORCID,Lollini Pier-Luigi¹

Affiliation:

1. Laboratory of Immunology and Biology of Metastasis, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy

2. Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

3. Rizzoli Orthopedic Institute, Laboratory of Experimental Oncology, Bologna, Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Association for Cancer Research (AIRC)

Department of Experimental, Diagnostic and Specialty Medicine of the University of Bologna (DIMES)

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1465164

Reference33 articles.

1. Cancer immunoprevention

2. Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice

3. Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine

4. Vaccines for tumour prevention

5. Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists;Expert Opinion on Biological Therapy;2023-08-20

2. Cancer immunotherapy: Recent advances and challenges;Journal of Cancer Research and Therapeutics;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3